Anti-Infectives

Global Anti-Infectives Market to Reach US$231.3 Billion by 2030

The global market for Anti-Infectives estimated at US$161.0 Billion in the year 2024, is expected to reach US$231.3 Billion by 2030, growing at a CAGR of 6.2% over the analysis period 2024-2030. Anti-Viral Drugs, one of the segments analyzed in the report, is expected to record a 7.3% CAGR and reach US$117.1 Billion by the end of the analysis period. Growth in the Anti-Fungal Drugs segment is estimated at 4.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$41.3 Billion While China is Forecast to Grow at 10.2% CAGR

The Anti-Infectives market in the U.S. is estimated at US$41.3 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$57.6 Billion by the year 2030 trailing a CAGR of 10.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.3% and 4.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.2% CAGR.

Anti-Infectives - Key Trends and Drivers

Anti-infectives are a cornerstone of modern medicine, comprising a diverse range of drugs designed to combat infections caused by bacteria, viruses, fungi, and parasites. This broad category includes antibiotics, antivirals, antifungals, and antiparasitics, each playing a crucial role in treating various infectious diseases. The development and use of anti-infectives have significantly reduced morbidity and mortality rates, revolutionizing the treatment of diseases that were once considered deadly. Over the past few decades, innovations in biotechnology and pharmaceutical research have led to the discovery of novel compounds and the enhancement of existing drugs, improving their efficacy and reducing side effects. The ongoing challenge of antibiotic resistance remains a significant focus within this field. The overuse and misuse of antibiotics have accelerated the emergence of drug-resistant strains of pathogens, posing a serious threat to public health. Consequently, substantial investment in research and development is directed towards discovering new antibiotics and alternative therapies, including bacteriophages, monoclonal antibodies, and immunotherapies, to combat resistant infections.

Global health trends and the epidemiology of infectious diseases heavily influence the anti-infectives market. The emergence of new pathogens, such as the novel coronavirus responsible for COVID-19, has underscored the critical need for robust anti-infective strategies. Large-scale vaccination programs, public health initiatives, and improved sanitation have played significant roles in controlling infectious diseases. However, the persistent threat of infections necessitates ongoing advancements in anti-infective drugs. Rapid progress in diagnostic technologies has also been instrumental, enabling quicker and more accurate detection of infections. This supports timely and appropriate treatment, reducing the burden of infectious diseases. Moreover, globalization, increased international travel, and trade have heightened the risk of cross-border transmission of infectious diseases, making a well-equipped arsenal of anti-infective drugs indispensable. Efforts to monitor and control outbreaks through advanced surveillance systems and international cooperation further highlight the market`s dynamic nature and the need for continual innovation.

The growth in the anti-infectives market is driven by several factors. Technological advancements in drug discovery and development, such as high-throughput screening, artificial intelligence, and genomic studies, have accelerated the identification of potential anti-infective agents. These technologies allow for more precise targeting of pathogens, improving drug efficacy and reducing the likelihood of resistance development. The rising prevalence of chronic diseases and immunocompromised conditions, such as cancer, diabetes, and HIV, which increase susceptibility to infections, has heightened the demand for effective anti-infective therapies. Consumer behavior also plays a significant role, with increasing awareness and a proactive approach towards health and wellness contributing to market expansion. The expansion of healthcare infrastructure in emerging markets and improved access to healthcare services has further boosted the consumption of anti-infectives. Regulatory incentives, such as fast-track approvals and funding for antimicrobial resistance research, support the growth of this market. Collaborations between pharmaceutical companies, academic institutions, and government bodies are fostering innovation and development in the field, ensuring a continuous pipeline of new and effective anti-infective agents. Additionally, public-private partnerships and global health initiatives are crucial in addressing the unmet needs in the anti-infectives market, promoting the development and distribution of essential medicines to combat infectious diseases worldwide.

SCOPE OF STUDY:

The report analyzes the Anti-Infectives market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Type (Anti-Viral Drugs, Anti-Fungal Drugs, Anti-Bacterial Drugs)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 17 Featured) -

• Allergan PLC
• Bayer AG
• Bristol-Myers Squibb Company
• F. Hoffmann-La Roche AG
• Gilead Sciences, Inc.
• GlaxoSmithKline PLC
• Johnson & Johnson
• Merck & Co., Inc.
• Novartis International AG
• Pfizer, Inc.
• Sanofi

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.